| Literature DB >> 29310643 |
Mariia Nagalievska1, Mariya Sabadashka2, Halyna Hachkova2, Nataliia Sybirna2.
Abstract
BACKGROUND: An impaired leukocytes function is the factor causing the susceptibility of patients with diabetes mellitus to infections. The outmost importance for the understanding of the immunological processes involved in diabetes pathogenesis is to give the characteritics of the immunological profile and changes therein, during the course of desease. Long-used in folk medicine to treat diabetes Galega officinalis L. has been chosen for the correction of the immune system dysfunction.Entities:
Keywords: Diabetes mellitus; Galega officinalis L.; Immunocompetent cells
Mesh:
Substances:
Year: 2018 PMID: 29310643 PMCID: PMC5759189 DOI: 10.1186/s12906-017-2079-3
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 4Changes in average cytochemical coefficient (ACC) of myeloperoxidase and cationic proteins under Galega officinalis extract administration in normal conditions and in the case of experimental diabetes mellitus
Qualitative and quantitative analysis of biologically active substances in chloroform fraction of Galega officinalis extract
| Peak no | R.T., min. | Name of the compound | Peak Area % |
|---|---|---|---|
| 1. | 10,186 | Not identified | 5,24 |
| 2. | 10,222 | MOME inositol | 2,08 |
| 3. | 10,638 | Tetradecanoic acid | 0,74 |
| 4. | 11,215 | Neophytadiene | 0,83 |
| 5. | 11,251 | 2-pentadecanone, 6, 10, 14-trimethyl | 0,58 |
| 6. | 12.053 | Hexadecanoic acid, ethyl ester | 15,79 |
| 7. | 12.232 | Hexadecanoic acid, ethyl ester | 0,85 |
| 8. | 12.642 | Not identified | 2,06 |
| 9. | 12.999 | Phytol | 3,62 |
| 10. | 13.201 | 9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)- | 17,82 |
| 11. | 13.290 | Octadecanoic acid | 1,67 |
| 12. | 13.332 | 9,12,15-Octadecatrien-1-ol, (Z,Z,Z)- | 1,52 |
| 13. | 15.151 | Not identified | 0,66 |
| 14. | 15.235 | Hexadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester | 0,95 |
| 15. | 15.455 | Phthalic acid, 2-ethylhexyl isohexyl ester | 8,33 |
| 16. | 16.085 | 2H-1-Benzopyran-7-ol, 3-(2,4-dimethoxyphenyl)-3,4-dihydro- | 1,88 |
| 17. | 16.162 | Eicosane | 0,83 |
| 18. | 16.198 | Nonanoic acid, 9-(3-hexenylidenecyclopropylidene)-,2-hydroxy-1-(hydroxymethyl)ethyl ester (Z,Z,Z)- | 1,28 |
| 19. | 16.287 | 6a,12a–dihydro-6H-(1,3)dioxolo(5,6)benzofuro(3,2-c)chromen-3-ol | 1,01 |
| 20. | 16.691 | Not identified | 0,89 |
| 21. | 16.816 | Squalene | 1,67 |
| 22. | 17.102 | Eicosane | 0,62 |
| 23. | 18.499 | Vitamin E | 0,66 |
| 24. | 19.278 | Campesterol | 1,98 |
| 25. | 19.522 | Stigmasterol | 4,06 |
| 26. | 20.015 | Stigmasterol | 11,63 |
| 27. | 20.390 | alpha.-Amyrin | 3,18 |
| 28. | 20.705 | 9,19-Cycloergost-24(28)-en-3-ol, 4,14,-dimethyl-, (3.beta.,4.alpha.,5.alpha.) - | 1,92 |
| 29. | 20.824 | alpha.-Amyrin | 2,56 |
| 30. | 21.317 | Not identified | 1,38 |
| 31. | 22.197 | Neophytadiene | 1,71 |
Fig. 1Chromatogram of biologically active substances in chloroform fraction of Galega officinalis extract
Fig. 2Effect of Galega officinalis extract on the proliferative activity of bone marrow cells of healthy and diabetic rats. * – P < 0.05 compared with controls. # – P < 0.05 compared with diabetic rats. § – P < 0.05 compared with control and diabetic rats
The ratio (in %) of neutrophils and lymphocytes precursors in the bone marrow of control animals, animals with diabetes mellitus and under the condition of Galega officinalis extract administration
| Cell type | C | C + G | D | D + G |
|---|---|---|---|---|
|
| ||||
| Myeloblasts | 1.91 ± 0.15 | 0.84 ± 0.09* | 1.46 ± 0.12 | 1.26 ± 0.09 |
| Metamyelocyte | 18.54 ± 1.21 | 13.53 ± 0.89* | 12.78 ± 1.39* | 12.42 ± 1.17* |
| Juvenile (band) and staff (stab) neutrophils | 15.67 ± 1.38 | 13.89 ± 0.28 | 10.84 ± 1.86 | 13.04 ± 0.83 |
| Segmented neutrophils | 1.58 ± 0.14 | 0.56 ± 0.07* | 1.1 ± 0.15 | 0.67 ± 0.09§ |
| Basophils of all types | 0.19 ± 0.12 | 0.11 ± 0.08 | 0.44 ± 0.05 | – |
| Eosinophils of all types | 0.40 ± 0.06 | 0.37 ± 0.19 | 0.32 ± 0.08 | 0.41 ± 0.13 |
|
| ||||
| Lymphoblasts | 34.31 ± 1.74 | 38.56 ± 2.07 | 49.48 ± 2.67* | 40.26 ± 1.94§ |
| Lymphocytes | 27.40 ± 3.03 | 32.13 ± 2.85 | 23.60 ± 2.36 | 30.95 ± 1.81# |
* – P < 0.05 compared with controls. # – P < 0.05 compared with diabetic rats. § – P < 0.05 compared with control and diabetic rats
Fig. 3Effect of Galega officinalis extract on the level of TNF-α in plasma of healthy and diabetic rats
Apoptotic lymphocytes detection by binding the surface of cells with annexin V and staining with PI under the administration of Galega officinalis extract in normal conditions and under experimental diabetes mellitus
| Cell viability, % | ||||
|---|---|---|---|---|
| C | C + G | D | D + G | |
| Viable cells | 96,41 ± 1,70 | 99,51 ± 0,07 | 87,56 ± 1,12* | 98,12 ± 0,26# |
| Cells with features of early apoptosis | 2,75 ± 1,92 | 0,11 ± 0,04* | 10,38 ± 0,58* | 1,39 ± 0,31# |
| Cells with features of late apoptosis | 0,06 ± 0,02 | 0,004 ± 0,002 | 0,16 ± 0,08* | 0,04 ± 0,02# |
| Cells with features of necrosis | 0,78 ± 0,30 | 0,38 ± 0,06* | 1,91 ± 1,76 | 0,44 ± 0,07# |
* – P < 0.05 compared with controls. # – P < 0.05 compared with diabetic rats
Fig. 5The two-dimensional histogram of apoptotic and viable lymphocytes distribution in DotPlot mode. On the horizontal axis - the intensity of annexin V - FITC fluorescence, the vertical axis - the intensity of PI fluorescence. Q3 (annexin V−/ PI−) - viable cells; Q4 (annexin V+/PI−) - cells with features of early apoptosis; Q2 (annexin V+/PI+) - cells with features of late apoptosis; Q1 (annexin V−/PI+) - cells with features of necrosis